CD40 and neoplasm: When we characterized the DC subsets during BRAFi therapy, more CD40+ activated, migratory cDC1 arrived in tumor-draining LN during BRAFi-sensitive phase, whereas percentages of CD40+ migratory CD64– cDC2 and CD64+ cDC2 were unchanged.